Galantamine-bound chitosan nanoparticles (G-NPs) administered intranasally to a rat model of scopolamine-induced AD reduced Aβ deposition and suppressed Notch signaling, outperforming conventional GAL therapy [181]. This evidence concerns the gene GAL and Alzheimer disease.